Cipla Receives USFDA Approval for Generic Voltaren® Gel (Diclofenac Sodium Topical Gel, 1%)

Cipla Limited (“Cipla”) announced that it has received final approval on August 3, 2018, for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 1% from the United States Food and Drug Administration (US FDA).

47% of asthma patients fear social stigma more than the disease itself.” – Nikhil Chopra, EVP and head, India Business, Cipla

In the brand’s latest ad, Priyanka Chopra’s revelation of being an asthmatic is set to dilute the bad buzz around asthma and inhalers.

World Asthma Day: Helping The World Breathefree

Cipla and Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

Indore Marathon 2019

All charged up, 155 Ciplaites participated in the #IndoreMarathon2019, here’s a glimpse of their sweet victory. #AIM #RunIndoreRun

Cipla receives final approval for generic version of Eli Lilly & Co.’s Adcirca® (Tadalafil Tablets 20mg)

Dr. Hamied recognized amongst India Today’s 20 Global Indians for his instrumental role in the fight against HIV and AIDS

Global Supply Chain Launches SCM Achievers Awards

Cipla receives final approval for generic version of Pfizer’s Depo-Provera® (Medroxyprogesterone Injectable, 150mg/mL)

Of Patents and Patients

Subscribe to